Brella SweatControl Patch
Three-minute targeted alkali thermolysis for underarm sweat reduction
About This Treatment
Brella is a single-use in-office sweat-reduction patch applied for about 3 minutes. In the United States, it received De Novo authorization on April 7, 2023 for adults with primary axillary hyperhidrosis.
It offers a low-downtime option for patients who want to avoid injections or nightly medication, using targeted alkali thermolysis (TAT) to deliver localized thermal energy to underarm sweat glands. At present it is mainly a US-centered treatment, and regulatory status in other regions should be checked individually.
Mechanism of Action
The alkali component reacts with water in sweat to generate localized heat, creating controlled microthermal injury in eccrine glands and temporarily reducing sweat output. It is distinguished by being needle-free and aluminum-free.
Indications
Expected Results
Clinical studies showed improvement in axillary sweat severity after a single treatment, with effect commonly lasting around 3-4 months. Some patients notice improvement within days, and repeat treatment can be used for maintenance.
Clinical Evidence
Risks & Side Effects
Transient redness, irritation, warmth, swelling, and superficial skin reactions are the main risks. Local discomfort or color change can occasionally persist, and temporary changes in sweat or odor pattern should be discussed.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition